TY - JOUR
T1 - Clinical and Economic Burden of Hyperkalemia
T2 - A Nationwide Hospital-Based Cohort Study in Japan
AU - Kanda, Eiichiro
AU - Kashihara, Naoki
AU - Kohsaka, Shun
AU - Okami, Suguru
AU - Yajima, Toshitaka
N1 - Funding Information:
This study and the corresponding analyses were supported and funded by AstraZeneca K.K., Japan. The authors from the funding source participated in the organization of study design, interpretation of results, contribution to manuscript drafts and revisions, and the decision to approve publication of the finished manuscript.
Funding Information:
Eiichiro Kanda, MD, PhD, MPH, Naoki Kashihara, MD, PhD, Shun Kohsaka, MD, Suguru Okami, PhD, and Toshitaka Yajima, MD, PhD. Conception and design: all authors; analysis and interpretation of data: SO, TK, SK, and EK. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated or resolved. This study and the corresponding analyses were supported and funded by AstraZeneca K.K. Japan. The authors from the funding source participated in the organization of study design, interpretation of results, contribution to manuscript drafts and revisions, and the decision to approve publication of the finished manuscript. Dr Kohsaka reports investigator-initiated grant funding from Bayer and Daiichi Sankyo and personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, and Pfizer. Drs Okami and Yajima are employed by AstraZeneca. The remaining authors declare that they have no relevant financial interests. The authors thank Masafumi Okada, ZhenZhen Fang, Yiyun Lin, and all project members of IQVIA Solutions, K.K. for providing technical and editorial support for this study. Received February 3, 2020. Evaluated by 1 external peer reviewer, with direct editorial input from the Statistical Editor, an Associate Editor, and the Editor-in-Chief. Accepted in revised form September 27, 2020.
Publisher Copyright:
© 2020 The Authors
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Rationale & Objective: Hyperkalemia is a common electrolyte abnormality of chronic kidney disease and heart failure associated with increased mortality and morbidity. We aimed to assess the long-term economic burden of hyperkalemia. Design: Observational cohort study using a Japanese nationwide hospital claims database (April 1, 2008, to September 30, 2018). Setting & Population:: Patients 18 years or older with at least 1 serum potassium value (N = 1,208,894). Exposures: Hyperkalemia defined with the presence of at least 2 serum potassium values ≥ 5.1 mmol/L. Outcome Measures: Direct health care costs and resource use in patients with hyperkalemia within and after 12 months from first hyperkalemia episodes. Analytical Approach: Health care costs and resource use were compared with propensity score–matched or nonmatched normokalemic controls. Multivariable regression analysis was performed to examine factors associated with health care costs. Results: 27,534 patients with hyperkalemia and 233,098 normokalemic controls were studied. Mean ± SD age was 73±13 years in patients with hyperkalemia; among them, 59% and 35% had chronic kidney disease and heart failure, respectively. In the propensity score–matched cohort (n = 5,859 in each group), average numbers of hospitalizations per patient per year in patients with hyperkalemia within and after 12 months were 1.2 and 1.6 times higher, respectively, compared with those in patients with normokalemia. The total cost per patient in patients with hyperkalemia was higher than for controls, with mean differences of $8,611 (95% CI, $8,046-$9,175) within 12 months and $5,150 (95% CI, $4,733-$5,566) after 12 months. The number of repeat hyperkalemic episodes was the factor with the strongest association with long-term health care costs, whereas severity of hyperkalemia was not associated. Limitations: This study used secondary data; therefore, residual confounders may not be fully excluded. Conclusions: Hyperkalemia was associated with significant long-term economic burden with frequent hospitalizations due to recurrent episodes, indicating the importance of hyperkalemia treatment for the sake of reducing health economic burdens and clinical complications.
AB - Rationale & Objective: Hyperkalemia is a common electrolyte abnormality of chronic kidney disease and heart failure associated with increased mortality and morbidity. We aimed to assess the long-term economic burden of hyperkalemia. Design: Observational cohort study using a Japanese nationwide hospital claims database (April 1, 2008, to September 30, 2018). Setting & Population:: Patients 18 years or older with at least 1 serum potassium value (N = 1,208,894). Exposures: Hyperkalemia defined with the presence of at least 2 serum potassium values ≥ 5.1 mmol/L. Outcome Measures: Direct health care costs and resource use in patients with hyperkalemia within and after 12 months from first hyperkalemia episodes. Analytical Approach: Health care costs and resource use were compared with propensity score–matched or nonmatched normokalemic controls. Multivariable regression analysis was performed to examine factors associated with health care costs. Results: 27,534 patients with hyperkalemia and 233,098 normokalemic controls were studied. Mean ± SD age was 73±13 years in patients with hyperkalemia; among them, 59% and 35% had chronic kidney disease and heart failure, respectively. In the propensity score–matched cohort (n = 5,859 in each group), average numbers of hospitalizations per patient per year in patients with hyperkalemia within and after 12 months were 1.2 and 1.6 times higher, respectively, compared with those in patients with normokalemia. The total cost per patient in patients with hyperkalemia was higher than for controls, with mean differences of $8,611 (95% CI, $8,046-$9,175) within 12 months and $5,150 (95% CI, $4,733-$5,566) after 12 months. The number of repeat hyperkalemic episodes was the factor with the strongest association with long-term health care costs, whereas severity of hyperkalemia was not associated. Limitations: This study used secondary data; therefore, residual confounders may not be fully excluded. Conclusions: Hyperkalemia was associated with significant long-term economic burden with frequent hospitalizations due to recurrent episodes, indicating the importance of hyperkalemia treatment for the sake of reducing health economic burdens and clinical complications.
KW - Hyperkalemia
KW - chronic kidney disease (CKD)
KW - health economics
KW - healthcare cost
KW - heart failure (HF)
UR - http://www.scopus.com/inward/record.url?scp=85096579500&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096579500&partnerID=8YFLogxK
U2 - 10.1016/j.xkme.2020.09.003
DO - 10.1016/j.xkme.2020.09.003
M3 - Article
AN - SCOPUS:85096579500
SN - 2590-0595
VL - 2
SP - 742-752.e1
JO - Kidney Medicine
JF - Kidney Medicine
IS - 6
ER -